Palisade Bio (PALI) Competitors $0.75 -0.03 (-3.46%) Closing price 04:00 PM EasternExtended Trading$0.76 +0.01 (+0.93%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PALI vs. NEUP, MBIO, NKGN, ERNA, FLGC, ME, IMNN, PMN, TRIB, and IBIOShould you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Neuphoria Therapeutics (NEUP), Mustang Bio (MBIO), NKGen Biotech (NKGN), Ernexa Therapeutics (ERNA), Flora Growth (FLGC), 23andMe (ME), Imunon (IMNN), Promis Neurosciences (PMN), Trinity Biotech (TRIB), and iBio (IBIO). These companies are all part of the "pharmaceutical products" industry. Palisade Bio vs. Its Competitors Neuphoria Therapeutics Mustang Bio NKGen Biotech Ernexa Therapeutics Flora Growth 23andMe Imunon Promis Neurosciences Trinity Biotech iBio Neuphoria Therapeutics (NASDAQ:NEUP) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Is NEUP or PALI more profitable? Neuphoria Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity.Company Net Margins Return on Equity Return on Assets Neuphoria TherapeuticsN/A N/A N/A Palisade Bio N/A -178.96%-127.35% Which has more risk and volatility, NEUP or PALI? Neuphoria Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Do institutionals and insiders have more ownership in NEUP or PALI? 15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 0.7% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 3.3% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to NEUP or PALI? In the previous week, Palisade Bio had 5 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 6 mentions for Palisade Bio and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 1.87 beat Palisade Bio's score of 0.66 indicating that Neuphoria Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Neuphoria Therapeutics Very Positive Palisade Bio Positive Which has better earnings & valuation, NEUP or PALI? Palisade Bio has higher revenue and earnings than Neuphoria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuphoria Therapeutics$10K1,445.72-$15.49MN/AN/APalisade Bio$250K14.46-$14.44M-$6.80-0.11 Do analysts rate NEUP or PALI? Neuphoria Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 173.08%. Palisade Bio has a consensus target price of $12.00, suggesting a potential upside of 1,493.63%. Given Palisade Bio's higher possible upside, analysts plainly believe Palisade Bio is more favorable than Neuphoria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPalisade Bio beats Neuphoria Therapeutics on 7 of the 12 factors compared between the two stocks. Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition Export to ExcelMetricPalisade BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.74M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E Ratio-0.117.5819.7619.92Price / Sales14.46292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book0.287.638.045.49Net Income-$14.44M-$55.05M$3.18B$250.27M7 Day Performance3.86%8.54%3.72%4.78%1 Month Performance14.93%5.38%3.72%7.20%1 Year Performance-83.23%2.35%29.92%17.27% Palisade Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio2.8406 of 5 stars$0.75-3.5%$12.00+1,493.6%-82.6%$3.74M$250K-0.1110News CoveragePositive NewsNEUPNeuphoria Therapeutics2.2575 of 5 stars$7.26+1.4%$21.00+189.3%N/A$13.65M$10K0.00N/AMBIOMustang Bio1.2133 of 5 stars$3.10-7.3%N/A-87.9%$13.56MN/A-0.04100News CoverageNKGNNKGen Biotech0.3357 of 5 stars$0.30flatN/A-74.2%$13.48MN/A-0.06N/ANews CoverageGap UpERNAErnexa Therapeutics0.6135 of 5 stars$1.83-8.6%N/A-92.6%$13.46M$535K-0.2210News CoverageFLGCFlora Growth2.6305 of 5 stars$0.60+1.9%$4.00+572.3%-29.9%$13.43M$59.51M-0.61280Positive NewsME23andMeN/A$0.50-35.3%N/A-94.6%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeIMNNImunon2.1067 of 5 stars$0.75+3.2%$15.50+1,958.4%-51.5%$13.19MN/A-0.5530PMNPromis Neurosciences3.3463 of 5 stars$0.41+0.1%$4.50+1,000.2%-82.3%$13.17MN/A-8.065Positive NewsGap UpTRIBTrinity Biotech1.0423 of 5 stars$0.72-1.8%N/A-73.0%$13.14M$61.56M-0.26480Gap DownIBIOiBio1.3977 of 5 stars$0.78-0.8%$4.30+452.7%-58.3%$12.80M$375K0.00100 Related Companies and Tools Related Companies NEUP Alternatives MBIO Alternatives NKGN Alternatives ERNA Alternatives FLGC Alternatives ME Alternatives IMNN Alternatives PMN Alternatives TRIB Alternatives IBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PALI) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
